Results 251 to 260 of about 58,392 (301)
Some of the next articles are maybe not open access.
Clinical Oncology, 1999
Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment.
R B, Buchanan, V J, Lewington
openaire +5 more sources
Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment.
R B, Buchanan, V J, Lewington
openaire +5 more sources
Radionuclide therapy of the thyroid
European Journal of Nuclear Medicine, 1991Radionuclide therapy has a proven place in the management of patients with thyroid disease. Iodine-131 therapy has been established as both successful and safe in treating patients with thyrotoxicosis and thyroid malignancy. Protocols for patient treatment are now standardised, although some variation in practice exists across Europe.
openaire +2 more sources
Radionuclide therapy revisited
European Journal of Nuclear Medicine, 1991Apart from its use in endocrinology and rheumatology, therapeutic nuclear medicine is developing rapidly as an additional treatment modality in oncology. Many different specific tumour-seeking radiopharmaceuticals are being applied both for diagnostic scintigraphy and treatment, using multiple routes and mechanisms to target radionuclides at tumours ...
openaire +2 more sources
Annals of Nuclear Medicine, 1998
Therapeutic nuclear medicine is rapidly developing as an additional treatment modality in oncology. Its unique characteristics are the systemic, yet selective delivery of radiation doses in target tissues, its non-invasiveness, the relative lack of immediate and late side effects, and the advantage that uptake and retention in the tumor can be pre ...
openaire +2 more sources
Therapeutic nuclear medicine is rapidly developing as an additional treatment modality in oncology. Its unique characteristics are the systemic, yet selective delivery of radiation doses in target tissues, its non-invasiveness, the relative lack of immediate and late side effects, and the advantage that uptake and retention in the tumor can be pre ...
openaire +2 more sources
Physics Today, 2000
Each year in the US, about 200 000 patients receive therapy with radionuclides, most commonly in the form of sealed sources for treating gynecological and head and neck cancers and radiopharmaceuticals for treating thyroid cancer. Known as brachytherapy, this kind of treatment has attracted a resurgence of interest in the medical world, primarily ...
Bert M. Coursey, Ravinder Nath
openaire +1 more source
Each year in the US, about 200 000 patients receive therapy with radionuclides, most commonly in the form of sealed sources for treating gynecological and head and neck cancers and radiopharmaceuticals for treating thyroid cancer. Known as brachytherapy, this kind of treatment has attracted a resurgence of interest in the medical world, primarily ...
Bert M. Coursey, Ravinder Nath
openaire +1 more source
2009
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source
Radionuclides and therapy of thyroid cancer
Nuclear Medicine Communications, 1993The majority of thyroid carcinomas are removed surgically. The appropriate surgical technique is still debated. After surgery the amount of residual thyroid or tumour and the presence of local or distant metastases is often in doubt, particularly if it is not detectable clinically. Therefore, methods for determining the presence of disease or the later
O'Doherty, M J, Nunan, T O, Croft, D N
openaire +2 more sources
Recent advances in radionuclide therapy
Seminars in Nuclear Medicine, 2001A variety of radionuclides continue to be investigated and/or clinically used for different therapeutic applications in nuclear medicine. The choice of a particular radionuclide with regard to appropriate emissions, linear energy transfer, and physical half-life is dictated to a large extent by the character of the disease (eg, solid tumor or ...
S, Srivastava, E, Dadachova
openaire +2 more sources
Radionuclide Therapy for Neuroendocrine Tumors
Current Oncology Reports, 2017Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, 90Y-DOTATOC and 177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of ...
CIVES, MAURO, Strosberg, Jonathan
openaire +3 more sources
Targeted Radionuclide Therapy of Melanoma
Seminars in Nuclear Medicine, 2016An estimated 60,000 individuals in the United States and 132,000 worldwide are yearly diagnosed with melanoma. Until recently, treatment options for patients with stages III-IV metastatic disease were limited and offered marginal, if any, improvement in overall survival. The situation changed with the introduction of B-RAF inhibitors and anti-cytotoxic
Abdullah, Norain, Ekaterina, Dadachova
openaire +2 more sources